PROBIOTICS PRESCRIBED WITH HELICOBACTER PYLORI ERADICATION
THERAPY IN EUROPE: USAGE PATTERN, EFFECTIVENESS, AND SAFETY:
Results from the European Registry on Helicobacter pylori
Management (Hp-EuReg)

J 2025

PROBIOTICS PRESCRIBED WITH HELICOBACTER PYLORI ERADICATION THERAPY IN EUROPE: USAGE PATTERN, EFFECTIVENESS, AND SAFETY: Results from the European Registry on Helicobacter pylori Management (Hp-EuReg)

DEZA, Diego Casas; Javier ALCEDO; Miguel LAFUENTE; F Javier LÓPEZ; Ángeles PEREZ-AISA et. al.

Základní údaje

Originální název

PROBIOTICS PRESCRIBED WITH HELICOBACTER PYLORI ERADICATION THERAPY IN EUROPE: USAGE PATTERN, EFFECTIVENESS, AND SAFETY: Results from the European Registry on Helicobacter pylori Management (Hp-EuReg)

Autoři

DEZA, Diego Casas; Javier ALCEDO; Miguel LAFUENTE; F Javier LÓPEZ; Ángeles PEREZ-AISA; Matteo PAVONI; Bojan TEPES; Laimas JONAITIS; Manuel CASTRO-FERNANDEZ; Manuel PABÓN-CARRASCO; Alma KECO-HUERGA; Irina VOYNOVAN; Luis BUJANDA; Alfredo J LUCENDO; Natasa Brglez JURECIC; Maja DENKOVSKI; Ludmila VOLOGZANINA; Luis RODRIGO; Samuel J MARTÍNEZ-DOMÍNGUEZ; Galyna FADIEIENKO; Jose M HUGUET; Rustam ABDULKHAKOV; Sayar R ABDULKHAKOV; Noelia ALCAIDE; Benito VELAYOS; Luis HERNÁNDEZ; Dmitry S BORDIN; Antonio GASBARRINI; Juozas KUPCINSKAS; Gülüstan BABAYEVA; Oleksiy GRIDNYEV; Mārcis LEJA; Theodore ROKKAS; Ricardo MARCOS-PINTO; Frode LERANG; Doron BOLTIN; Antonio MESTROVIC; Sinead M SMITH; Marino VENERITO; Lyudmila BOYANOVA; Vladimir MILIVOJEVIC; Michael DOULBERIS; Lumír KUNOVSKÝ; Pablo PARRA; Anna CANO-CATALÀ; Leticia MOREIRA; Olga P NYSSEN; Francis MEGRAUD; Colm O MORAIN a Javier P GISBERT

Vydání

American Journal of Gastroenterology, PHILADELPHIA, LIPPINCOTT WILLIAMS & WILKINS, 2025, 0002-9270

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30219 Gastroenterology and hepatology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 7.600 v roce 2024

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.14309/ajg.0000000000003351

UT WoS

999

EID Scopus

999

Štítky

14110223

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 26. 2. 2025 12:36, Mgr. Tereza Miškechová

Anotace

V originále

Aim: To evaluate the prescriptions patterns, effectiveness, and safety of adding probiotics to Helicobacter pylori eradication therapy, in Europe. Design: International, prospective, non-interventional registry of the clinical practice of the European gastroenterologists. Data were collected and quality reviewed until March 2021 at AEG-REDCap. The effectiveness was evaluated by modified intention-to-treat analysis, differentiating by geographic areas. Adverse events (AE) were categorized as mild, moderate, and severe. Results: Overall, 36,699 treatments were recorded, where 8,233 (22%) were prescribed with probiotics. Probiotics use was associated with higher effectiveness in the overall analysis (OR 1.631 [95% CI 1.456-1.828]), as well as in triple (1.702 [1.403-2.065]), quadruple (1.383 [0.996-1.920]), bismuth quadruple (1.248 [1.003-1.554] and sequential therapies (3.690 [2.686-5.069]). Lactobacillus genus was associated with a higher therapy effectiveness in Eastern Europe when triple (OR: 2.625 [CI 1.911, 3.606]) and bismuth quadruple (OR: 1.587 [CI 1.117, 2.254]) first-line therapies were prescribed. In Central Europe, the use of probiotics was associated with a decrease in both the overall incidence of AEs (0.656 [0.516, 0.888]) as well as severe AEs (0.312; [0.217, 0.449]). Bifidobacterium genus was associated with lower overall (OR: 0.725 [95% CI 0.592-0.888]) and severe (OR: 0.254 [0.185-0.347]) AEs; and Saccharomyces was associated with reduced overall (OR: 0.54 [CI 0.32-0.91]) and severe (OR 0.257 [CI 0.123-0.536]) AEs under quadruple-bismuth regimen. Conclusions: In Europe, the use of probiotics was associated with higher effectiveness and safety of H. pylori eradication therapy. Lactobacillus improved treatment effectiveness, while Bifidobacterium and Saccharomyces were associated with a better safety profile.

Citovat

@article{2480045,
   author = {Deza, Diego Casas and Alcedo, Javier and Lafuente, Miguel and López, F Javier and PerezandAisa, Ángeles and Pavoni, Matteo and Tepes, Bojan and Jonaitis, Laimas and CastroandFernandez, Manuel and PabónandCarrasco, Manuel and KecoandHuerga, Alma and Voynovan, Irina and Bujanda, Luis and Lucendo, Alfredo J and Jurecic, Natasa Brglez and Denkovski, Maja and Vologzanina, Ludmila and Rodrigo, Luis and MartínezandDomínguez, Samuel J and Fadieienko, Galyna and Huguet, Jose M and Abdulkhakov, Rustam and Abdulkhakov, Sayar R and Alcaide, Noelia and Velayos, Benito and Hernández, Luis and Bordin, Dmitry S and Gasbarrini, Antonio and Kupcinskas, Juozas and Babayeva, Gülüstan and Gridnyev, Oleksiy and Leja, Mārcis and Rokkas, Theodore and MarcosandPinto, Ricardo and Lerang, Frode and Boltin, Doron and Mestrovic, Antonio and Smith, Sinead M and Venerito, Marino and Boyanova, Lyudmila and Milivojevic, Vladimir and Doulberis, Michael and Kunovský, Lumír and Parra, Pablo and CanoandCatalà, Anna and Moreira, Leticia and Nyssen, Olga P and Megraud, Francis and Morain, Colm O and Gisbert, Javier P},
   article_location = {PHILADELPHIA},
   doi = {https://doi.org/10.14309/ajg.0000000000003351},
   language = {eng},
   issn = {0002-9270},
   journal = {American Journal of Gastroenterology},
   title = {PROBIOTICS PRESCRIBED WITH HELICOBACTER PYLORI ERADICATION THERAPY IN EUROPE: USAGE PATTERN, EFFECTIVENESS, AND SAFETY: Results from the European Registry on Helicobacter pylori Management (Hp-EuReg)},
   url = {https://journals.lww.com/ajg/abstract/9900/probiotics_prescribed_with_helicobacter_pylori.1573.aspx},
   year = {2025}
}

TY  - JOUR
ID  - 2480045
AU  - Deza, Diego Casas - Alcedo, Javier - Lafuente, Miguel - López, F Javier - Perez-Aisa, Ángeles - Pavoni, Matteo - Tepes, Bojan - Jonaitis, Laimas - Castro-Fernandez, Manuel - Pabón-Carrasco, Manuel - Keco-Huerga, Alma - Voynovan, Irina - Bujanda, Luis - Lucendo, Alfredo J - Jurecic, Natasa Brglez - Denkovski, Maja - Vologzanina, Ludmila - Rodrigo, Luis - Martínez-Domínguez, Samuel J - Fadieienko, Galyna - Huguet, Jose M - Abdulkhakov, Rustam - Abdulkhakov, Sayar R - Alcaide, Noelia - Velayos, Benito - Hernández, Luis - Bordin, Dmitry S - Gasbarrini, Antonio - Kupcinskas, Juozas - Babayeva, Gülüstan - Gridnyev, Oleksiy - Leja, Mārcis - Rokkas, Theodore - Marcos-Pinto, Ricardo - Lerang, Frode - Boltin, Doron - Mestrovic, Antonio - Smith, Sinead M - Venerito, Marino - Boyanova, Lyudmila - Milivojevic, Vladimir - Doulberis, Michael - Kunovský, Lumír - Parra, Pablo - Cano-Català, Anna - Moreira, Leticia - Nyssen, Olga P - Megraud, Francis - Morain, Colm O - Gisbert, Javier P
PY  - 2025
TI  - PROBIOTICS PRESCRIBED WITH HELICOBACTER PYLORI ERADICATION THERAPY IN EUROPE: USAGE PATTERN, EFFECTIVENESS, AND SAFETY: Results from the European Registry on Helicobacter pylori Management (Hp-EuReg)
JF  - American Journal of Gastroenterology
PB  - LIPPINCOTT WILLIAMS & WILKINS
SN  - 00029270
UR  - https://journals.lww.com/ajg/abstract/9900/probiotics_prescribed_with_helicobacter_pylori.1573.aspx
N2  - Aim: To evaluate the prescriptions patterns, effectiveness, and safety of adding probiotics to Helicobacter pylori eradication therapy, in Europe. Design: International, prospective, non-interventional registry of the clinical practice of the European gastroenterologists. Data were collected and quality reviewed until March 2021 at AEG-REDCap. The effectiveness was evaluated by modified intention-to-treat analysis, differentiating by geographic areas. Adverse events (AE) were categorized as mild, moderate, and severe. Results: Overall, 36,699 treatments were recorded, where 8,233 (22%) were prescribed with probiotics. Probiotics use was associated with higher effectiveness in the overall analysis (OR 1.631 [95% CI 1.456-1.828]), as well as in triple (1.702 [1.403-2.065]), quadruple (1.383 [0.996-1.920]), bismuth quadruple (1.248 [1.003-1.554] and sequential therapies (3.690 [2.686-5.069]). Lactobacillus genus was associated with a higher therapy effectiveness in Eastern Europe when triple (OR: 2.625 [CI 1.911, 3.606]) and bismuth quadruple (OR: 1.587 [CI 1.117, 2.254]) first-line therapies were prescribed. In Central Europe, the use of probiotics was associated with a decrease in both the overall incidence of AEs (0.656 [0.516, 0.888]) as well as severe AEs (0.312; [0.217, 0.449]). Bifidobacterium genus was associated with lower overall (OR: 0.725 [95% CI 0.592-0.888]) and severe (OR: 0.254 [0.185-0.347]) AEs; and Saccharomyces was associated with reduced overall (OR: 0.54 [CI 0.32-0.91]) and severe (OR 0.257 [CI 0.123-0.536]) AEs under quadruple-bismuth regimen. Conclusions: In Europe, the use of probiotics was associated with higher effectiveness and safety of H. pylori eradication therapy. Lactobacillus improved treatment effectiveness, while Bifidobacterium and Saccharomyces were associated with a better safety profile.
ER  -

Přehled o publikaci